<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914367</url>
  </required_header>
  <id_info>
    <org_study_id>2013/422</org_study_id>
    <secondary_id>2013-002340-90</secondary_id>
    <nct_id>NCT01914367</nct_id>
  </id_info>
  <brief_title>Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)</brief_title>
  <acronym>HPVXneutra001</acronym>
  <official_title>Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Six identical female twins aged 9-13 years will participate. One sib of each twin pair will&#xD;
      be given Cervarix according to the 0, 1, 6 month vaccination scheme, while the other sib will&#xD;
      be given Gardasil according to the 0, 2, 6 month vaccination scheme. Three blood samples will&#xD;
      be taken (the first prior to vaccine administration, the second and third 7 days after dose 2&#xD;
      and 3, respectively). The blood samples will be used to determine: 1) the magnitude the&#xD;
      anti-HPV 16 and anti-HPV-18 antibody responses, 2) as well as the cross-reactive pattern of&#xD;
      these responses towards related, non-vaccine HPV strains (HPV-31 and -33, and HPV-45). 3)&#xD;
      plasmablast isolated from blood taken 7 days after the 3rd dose in the first place (and&#xD;
      eventually after the 2nd dose also) will be examined for for the usage of VDJ and VJ segments&#xD;
      in the immunoglobulin heavy (VH) and light (VL) heavy and light chains. Gene useg in B cells&#xD;
      induced by Cervarix and Gardasil will be compared. Finally the cross-reactive potential of&#xD;
      monoclonal antibodies obtained by eukaryotic expression of a series of heavy (VH) and light&#xD;
      (VL) chains from single ASC isolated after the 3rd dose of a three-dose schedule of either&#xD;
      Cervarix or Gardasil will be examined.&#xD;
&#xD;
      The duration of the study is approximately 187 days. Five study visits will take place, over&#xD;
      a time period of 6.5 months, followed by a telephone call after 12 months.&#xD;
&#xD;
      The purpose of the study is to learn more about the molecular mechanisms underlying the&#xD;
      cross-neutralizing capacity of AS04-adjuvanted HPV vaccine (Cervarix®) in comparison with the&#xD;
      aluminiumhydroxyphosphate sulphate adjuvanted HPV vaccine (Gardasil®).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparing of VDJ and VJ segments in the immunoglobulin heavy and light chains/plasmablasts</measure>
    <time_frame>at day 187</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>comparing the mutational diversity that occurs following vaccine-induced affinity maturation in plasmablasts</measure>
    <time_frame>at day 187</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of the cross-reactive pattern of polyclonal serum antibodies</measure>
    <time_frame>at day 187</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparing of VDJ and VJ segment usage and affinity maturation in HPV-specific antibodies</measure>
    <time_frame>at day 187</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparing of the cross-reactive potential of monoclonal antibodies obtained by eukaryotic expression of a series of heavy (VH) and light (VL) chains from single ASC</measure>
    <time_frame>at day 187</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Infection With Human Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One sib of each twin pair will be given Cervarix according to the 0, 1, 6 month vaccination scheme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gardasil Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One sib of each twin pair will be given Gardasil according to the 0, 1, 6 month vaccination scheme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cervarix</intervention_name>
    <description>3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm</description>
    <arm_group_label>Cervarix group</arm_group_label>
    <other_name>GSK's commercially available bivalent HPV types 16 and 18 recombinant vaccine containing AS04 adjuvant (Cervarix®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm</description>
    <arm_group_label>Gardasil Group</arm_group_label>
    <other_name>Merck's commercially availably quadrivalent HPV(types 6, 11, 16, 18) recombinant vaccine containing amorphous aluminiumhydroxyphosphate sulphate adjuvant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Six homozygous twins in good health, without preceding sexual activity (virgin).&#xD;
             Subjects have a negative pregnancy test on the day of vaccination and have agreed to&#xD;
             continue abstinence during the entire study period and for two months after completion&#xD;
             of the vaccination series.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects are not participating in any other clinical trials and have not been&#xD;
             vaccinated previously against HPV and have not had an administration of MPL or AS04 in&#xD;
             the past.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert Leroux-Roels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geert Leroux-Roels, MD, PhD</last_name>
    <phone>+32 9 332 34 22</phone>
    <email>geert.lerouxroels@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geert Leroux-Roels, MD, PhD</last_name>
      <phone>+32 9 332 34 22</phone>
      <email>geert.lerouxroels@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Geert Leroux-Roels, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 6, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

